Veru Inc. (NASDAQ:VERU) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. lifted its stake in shares of Veru Inc. (NASDAQ:VERU) by 18.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,487 shares of the company’s stock after purchasing an additional 2,591 shares during the period. Victory Capital Management Inc.’s holdings in Veru were worth $133,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rhumbline Advisers lifted its holdings in shares of Veru by 4.9% in the 1st quarter. Rhumbline Advisers now owns 49,634 shares of the company’s stock worth $535,000 after acquiring an additional 2,327 shares during the last quarter. BlackRock Inc. increased its position in shares of Veru by 4.3% in the 1st quarter. BlackRock Inc. now owns 3,925,773 shares of the company’s stock valued at $42,301,000 after purchasing an additional 161,722 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of Veru in the 1st quarter valued at $465,000. New York State Common Retirement Fund boosted its stake in Veru by 5.5% during the 1st quarter. New York State Common Retirement Fund now owns 47,900 shares of the company’s stock worth $516,000 after purchasing an additional 2,500 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Veru by 19.3% in the 1st quarter. JPMorgan Chase & Co. now owns 160,778 shares of the company’s stock worth $1,733,000 after acquiring an additional 25,990 shares during the period. Hedge funds and other institutional investors own 30.61% of the company’s stock.

Shares of NASDAQ:VERU opened at $8.46 on Tuesday. Veru Inc. has a 52-week low of $2.30 and a 52-week high of $24.57. The business’s 50 day simple moving average is $7.84 and its two-hundred day simple moving average is $9.01. The firm has a market cap of $675.56 million, a P/E ratio of -845.15 and a beta of 0.63.

Veru (NASDAQ:VERU) last posted its quarterly earnings results on Thursday, August 12th. The company reported ($0.03) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.03. Veru had a negative return on equity of 7.62% and a negative net margin of 0.25%. On average, equities research analysts expect that Veru Inc. will post -0.19 earnings per share for the current year.

In related news, Director Lucy Lu acquired 4,800 shares of the firm’s stock in a transaction dated Tuesday, August 17th. The shares were purchased at an average price of $6.78 per share, for a total transaction of $32,544.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 24.60% of the company’s stock.

Several equities analysts have weighed in on the stock. Oppenheimer restated a “buy” rating and set a $26.00 target price on shares of Veru in a report on Friday, August 27th. Brookline Capital Management restated a “buy” rating on shares of Veru in a research report on Friday, August 27th. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Veru in a research report on Monday, June 28th. Finally, Zacks Investment Research downgraded shares of Veru from a “hold” rating to a “sell” rating in a report on Wednesday, August 11th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Veru currently has a consensus rating of “Buy” and an average target price of $17.46.

Veru Profile

Veru, Inc is an oncology biopharmaceutical company engaged in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT.

Featured Article: How are the companies in the S&P 500 selected?

Institutional Ownership by Quarter for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.